modelR06AX12

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Terfenadine
ATC code:R06AX12
route:oral
compartments:2
dosage:60mg
volume of distribution:11L
clearance:960ml/min
other parameters in model implementation

Terfenadine is a non-sedating antihistamine that was formerly used to treat allergic rhinitis and other allergy symptoms. It acts as an H1 receptor antagonist. Due to its association with QT prolongation and risk of serious arrhythmias (notably Torsades de Pointes), terfenadine has been withdrawn or discontinued in many countries and is no longer approved for clinical use.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult subjects following oral administration.

References

  1. Lalonde, RL, et al., & Gaudreault, J (1996). Population pharmacokinetics of terfenadine. Pharmaceutical research 13(6) 832–838. DOI:10.1023/a:1016036624935 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8792418

  2. Paton, DM, & Webster, DR (1985). Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clinical pharmacokinetics 10(6) 477–497. DOI:10.2165/00003088-198510060-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2866055

  3. Wilkinson, GR (1996). Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Journal of pharmacokinetics and biopharmaceutics 24(5) 475–490. DOI:10.1007/BF02353475 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9131486

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)